We came across a bullish thesis on ABIVAX Société Anonyme on Alpha Talon Investment Research’s Substack by AT Investment ...
In the midst of geopolitical uncertainties and fluctuating economic indicators, European markets have shown resilience, with ...
For the past couple of months, speculation has arisen that Eli Lilly, an American multinational pharmaceutical company, is pursuing a potential acquisition of ABIVAX Société Anonyme (NASDAQ:ABVX).
The average one-year price target for ABIVAX Société Anonyme (OTCPK:AAVXF) has been revised to $140.24 / share. This is an increase of 13.99% from the prior estimate of $123.02 dated November 16, 2025 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results